The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.
The companies will commercialize Predigraft, a data analysis tool that provides early predictions of risk for allograft rejection and transplant loss.
Vendors look to augment, not replace, genetic counselors with consumer-friendly technology, including AI-driven online chats and decision support systems.
Japanese software giant NEC invests in AI-centric software company BostonGene to advance immuno-oncology and other targeted cancer treatments.
Ardigen has expanded into immuno-oncology, microbiomics, epigenomics, and CRISPR data analysis to support drug development and precision medicine.
The partners will offer Onegevity's GutBio assay, which integrates metagenomic sequencing with AI-based personalized recommendations to improve gut health, in Japan.
French startup OmicX has built an AI-based search engine for omics-related knowledge to help biomedical researchers find protocols in published literature.
Cambridge Cancer Genomics will contribute AI, liquid biopsy technology, and a TMB sequencing panel to broaden access to cancer immunotherapies in the UK.
Singapore-based Lucence Diagnostics will team with Stanford to analyze sequencing and imaging of liver cancer patients to predict therapeutic effectiveness.
With the acquisition of Swiss healthcare AI specialist SimplicityBio, Precision for Medicine can offer new features in its QuartzBio multiomic data integration platform.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.